• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza and secondary bacterial infections: threats and treatments

tetano

Editor, Senior Moderator
Med Sci (Paris). 2017 May;33(5):528-533. doi: 10.1051/medsci/20173305017. Epub 2017 Jun 14.
[h=1][Influenza and secondary bacterial infections: threats and treatments].[/h] [Article in French]
Roquilly A[SUP]1[/SUP], Trottein F[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza virus infection ("flu") constitutes an important public health issue and is associated with a significant socio-economic burden. The discovery of new antivirals and a better understanding of antiviral immunity might offer new options for preventing or controlling flu infections. A better understanding of the underlying pathomechanism might also prompt the discovery of key molecules whose activity could be modulated in a clinical setting. Lastly, the development of new immunomodulators and immunostimulants might compensate for impaired host defense mechanisms and improve resistance to secondary bacterial infections, since the latter significantly worsen the clinical status of influenza-infected patients.
? 2017 m?decine/sciences ? Inserm.


PMID: 28612729 DOI: 10.1051/medsci/20173305017
 
Back
Top Bottom